Developer docs
API playgroundTry for free, no card

Search company profiles

Evoke Pharma

Full company profile

uuid0003qc3

Namestring
Evoke Pharma
Legal namestring
Evoke Pharma, Inc.
Websiteurl
evokepharma.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Evoke Pharma, Inc. is a specialty pharmaceutical company founded in 2007 and headquartered in Solana Beach, California, that develops and commercializes therapeutics for gastrointestinal diseases, with a single commercial product: GIMOTI (metoclopramide) nasal spray. GIMOTI is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis; it delivers metoclopramide via the nasal route, bypassing the gastrointestinal tract to provide more predictable absorption during gastroparesis flares or vomiting. The company commercializes GIMOTI exclusively in the United States through a partnership with EVERSANA Life Sciences, which provides sales, marketing, access and reimbursement, adherence, and product distribution services on Evoke's behalf.

Evoke generates revenue through net product sales of GIMOTI, with Q3 2025 net product sales of $4.3 million representing a 61% year-over-year increase, and a 2024 market projection of approximately $10.2 million in annual sales. A newly issued US patent extends GIMOTI's market exclusivity to November 2038, and the company has stated plans to expand its pipeline through in-licensing or acquisition of additional gastroenterology-focused products. The company was acquired by QOL Medical in December 2025 at $11.00 per share in cash (a 139.7% premium to its recent Nasdaq closing price) and is now a wholly owned subsidiary, with Evoke's common stock having ceased trading on Nasdaq on December 17, 2025. The company operates with a lean structure of 1-10 employees, relying on its EVERSANA partnership for end-to-end commercial execution in the US market.

Short descriptiontext

Evoke Pharma is a specialty pharmaceutical company that develops and commercializes GIMOTI, the first and only FDA-approved non-oral (nasal spray) treatment for diabetic gastroparesis, distributed in the United States via its commercialization partner EVERSANA.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSolana Beach, United States
HQ citystring
Solana Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, gastrointestinal therapeutics, nasal drug delivery, diabetic gastroparesis treatment, metoclopramide formulations
Industry2 codes
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
Product category
Specialty Pharmaceuticals — Gastrointestinal Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1GIMOTI Product Sales
TypeOne Time License
Description

Evoke Pharma generates revenue through net product sales of GIMOTI (metoclopramide) nasal spray. Q3 2025 net product sales reached $4.3 million, representing a 61% year-over-year increase. The company was acquired by QOL Medical in late 2025 for $11.00 per share.

biospace.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Marketing or Sales, Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1GIMOTI
Description

GIMOTI (metoclopramide) nasal spray is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (DGP).

evokepharma.com
Core offering1 text field

Evoke Pharma develops and commercializes GIMOTI, a metoclopramide nasal spray that is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The nasal route bypasses the gastrointestinal tract to provide more predictable drug absorption even during gastroparesis flares or vomiting, addressing a key gap left by oral metoclopramide approved since 1979. Evoke commercializes GIMOTI in the United States through a partnership with EVERSANA Life Sciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Healthcare cost savings of approximately $15,000 per patient within six months compared to oral metoclopramide
+3 more records
Product overview1 text field

Evoke Pharma is a specialty pharmaceutical company with a single core product: GIMOTI (metoclopramide) nasal spray. GIMOTI is the first and only FDA-approved non-oral treatment for diabetic gastroparesis, delivering the FDA-approved drug metoclopramide via nasal spray for more predictable absorption compared to oral administration. The company operates with a commercial partnership with EVERSANA Life Sciences for U.S. commercialization services and has plans to expand its pipeline through in-licensing or acquisition of additional gastroenterology-focused products.

Product and service1 record
1GIMOTI (metoclopramide) nasal spray
CategorySpecialty pharmaceutical — nasal spray gastrointestinal therapeutic
Description

GIMOTI is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It delivers metoclopramide through the nasal route, bypassing the gastrointestinal tract for more predictable absorption, and is also positioned to support patients on GLP-1 medications experiencing DGP symptoms.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-04
Description

Evoke Pharma entered into a definitive agreement to be acquired by QOL Medical at $11.00 per share in cash, representing a 139.7% premium to its recent Nasdaq closing price. The transaction was approved by both boards and expected to close in Q4 2025 through a tender offer followed by a merger. The tender offer expired on December 15, 2025 with 67.63% of shares tendered, and the merger was consummated making Evoke a wholly owned subsidiary of QOL Medical.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Evoke has an agreement with EVERSANA for the complete commercialization of GIMOTI in the United States. Through this partnership, Evoke leverages EVERSANA's suite of capabilities and experts to implement their commercial strategy. The collaboration offers seamless integrated advantage across sales, marketing, access and reimbursement services, adherence, product distribution, and other services.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Salix (now part of Bausch Health) is one of the largest US gastroenterology specialty pharmaceutical companies with a broad GI portfolio including treatments for IBS, bowel prep, and hepatic encephalopathy. Highly comparable business model of focused GI specialty drug commercialization, though at much larger scale than Evoke.

TypeDirect peer
Description

Ironwood commercializes LINZESS (linaclotide) for IBS-C and CIC, making it a direct GI specialty pharma peer. Both companies operate single-asset or focused-portfolio commercial models targeting gastroenterologists and primary care, with similar reliance on prescriber adoption and payer access.

TypeDirect peer
Description

RedHill is a specialty pharma focused on gastrointestinal diseases, with commercial products for H. pylori, IBS, and gastroenteritis. Highly comparable as a small-cap GI specialty commercial-stage company, though RedHill operates across multiple assets rather than a single product.

TypeDirect peer
Description

Ardelyx commercializes IBSRELA (tenapanor) and XPHOZAH for hyperphosphatemia, both targeting GI and renal specialists. Comparable as a small-cap GI-focused specialty commercial pharma with similar single-asset dynamics and prescriber-focused commercial model.

TypeDirect peer
Description

Phathom commercializes VOQUEZNA (vonoprazan) for H. pylori and erosive esophagitis. Directly comparable as a small-cap GI specialty commercial pharma with a novel mechanism product targeting gastroenterologists, with a similar prescriber-driven commercial model.

TypeDirect peer
Description

Sebela is a private specialty pharmaceutical company with multiple GI and women's health products, including treatments for bowel prep and IBS. Comparable as a privately held GI specialty pharma with similar commercial scale and prescriber-focused business model.

TypeOthers
Description

QOL Medical is the parent company that acquired Evoke Pharma in December 2025. Relevant as the strategic acquirer and now owner of GIMOTI; QOL focuses on rare and specialty diseases and is itself a small specialty pharma.

TypeRegional player
Description

US WorldMeds is a privately held specialty pharma with a portfolio spanning gastroenterology, rare diseases, and neurology. Comparable as a privately held specialty commercial-stage pharma with GI exposure, though broader in scope.

TypeEmerging player
Description

Napo (now Jaguar Health) commercializes Mytesi (crofelemer) for HIV-related diarrhea and is developing treatments for GI-related conditions. Comparable as a small specialty GI pharma with a single primary commercial asset and similar prescriber-focused commercialization dynamics.

TypeDirect peer
Description

Aytu BioPharma is a small specialty pharmaceutical company commercializing products in pediatrics, respiratory, and GI. Relevant as a small-cap specialty pharma with GI exposure and similar commercial scale dynamics; Aytu's CCO Greg Pyszczymuka recently joined Evoke's board, signaling industry overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evoke Pharma

Specialty Pharmaceuticals — Gastrointestinal Therapeuticsevokepharma.com

Evoke Pharma is a specialty pharmaceutical company that develops and commercializes GIMOTI, the first and only FDA-approved non-oral (nasal spray) treatment for diabetic gastroparesis, distributed in the United States via its commercialization partner EVERSANA.

What Evoke Pharma does

Evoke Pharma, Inc. is a specialty pharmaceutical company founded in 2007 and headquartered in Solana Beach, California, that develops and commercializes therapeutics for gastrointestinal diseases, with a single commercial product: GIMOTI (metoclopramide) nasal spray. GIMOTI is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis; it delivers metoclopramide via the nasal route, bypassing the gastrointestinal tract to provide more predictable absorption during gastroparesis flares or vomiting. The company commercializes GIMOTI exclusively in the United States through a partnership with EVERSANA Life Sciences, which provides sales, marketing, access and reimbursement, adherence, and product distribution services on Evoke's behalf.

Evoke generates revenue through net product sales of GIMOTI, with Q3 2025 net product sales of $4.3 million representing a 61% year-over-year increase, and a 2024 market projection of approximately $10.2 million in annual sales. A newly issued US patent extends GIMOTI's market exclusivity to November 2038, and the company has stated plans to expand its pipeline through in-licensing or acquisition of additional gastroenterology-focused products. The company was acquired by QOL Medical in December 2025 at $11.00 per share in cash (a 139.7% premium to its recent Nasdaq closing price) and is now a wholly owned subsidiary, with Evoke's common stock having ceased trading on Nasdaq on December 17, 2025. The company operates with a lean structure of 1-10 employees, relying on its EVERSANA partnership for end-to-end commercial execution in the US market.

Evoke Pharma firmographics

Firmographics
Name
Evoke Pharma
Legal name
Evoke Pharma, Inc.
Website
https://evokepharma.com
Company type
Public
Founded year
2007
Operating status
Acquired
Headcount range
11–50 employees
Short description
Evoke Pharma is a specialty pharmaceutical company that develops and commercializes GIMOTI, the first and only FDA-approved non-oral (nasal spray) treatment for diabetic gastroparesis, distributed in the United States via its commercialization partner EVERSANA.
Ownership category
akta.pro rank

Evoke Pharma industry classification

Industry
Product category
Specialty Pharmaceuticals — Gastrointestinal Therapeutics
akta.pro industry
PRIMARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SECONDARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Specialty pharmaceuticals
  • Gastrointestinal therapeutics
  • Nasal drug delivery
  • Diabetic gastroparesis treatment
  • Metoclopramide formulations

Where Evoke Pharma is headquartered

Location

Headquarters

HQ city
Solana Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Evoke Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Marketing or Sales, Personnel, Operations, Technology or R&D

Revenue model

  1. GIMOTI Product Sales: Evoke Pharma generates revenue through net product sales of GIMOTI (metoclopramide) nasal spray. Q3 2025 net product sales reached $4.3 million, representing a 61% year-over-year increase. The company was acquired by QOL Medical in late 2025 for $11.00 per share.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Evoke Pharma product offering

Product offering

Core offering

Evoke Pharma develops and commercializes GIMOTI, a metoclopramide nasal spray that is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The nasal route bypasses the gastrointestinal tract to provide more predictable drug absorption even during gastroparesis flares or vomiting, addressing a key gap left by oral metoclopramide approved since 1979. Evoke commercializes GIMOTI in the United States through a partnership with EVERSANA Life Sciences.

Product overview

Evoke Pharma is a specialty pharmaceutical company with a single core product: GIMOTI (metoclopramide) nasal spray. GIMOTI is the first and only FDA-approved non-oral treatment for diabetic gastroparesis, delivering the FDA-approved drug metoclopramide via nasal spray for more predictable absorption compared to oral administration. The company operates with a commercial partnership with EVERSANA Life Sciences for U.S. commercialization services and has plans to expand its pipeline through in-licensing or acquisition of additional gastroenterology-focused products.

Differentiator

Problem solved

Functional benefit

Brands

  • GIMOTI: GIMOTI (metoclopramide) nasal spray is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis (DGP).

Products and services

  • GIMOTI (metoclopramide) nasal spray GIMOTI is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It delivers metoclopramide through the nasal route, bypassing the gastrointestinal tract for more predictable absorption, and is also positioned to support patients on GLP-1 medications experiencing DGP symptoms.

Quantifiable outcome

  • Healthcare cost savings of approximately $15,000 per patient within six months compared to oral metoclopramide
  • +3 more outcomes

Companies that use Evoke Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Evoke Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Evoke Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • QOL MedicalcoreStrategic or Co-development Partner · 4 November 2025Evoke Pharma entered into a definitive agreement to be acquired by QOL Medical at $11.00 per share in cash, representing a 139.7% premium to its recent Nasdaq closing price. The transaction was approved by both boards and expected to close in Q4 2025 through a tender offer followed by a merger. The tender offer expired on December 15, 2025 with 67.63% of shares tendered, and the merger was consummated making Evoke a wholly owned subsidiary of QOL Medical.
  • EVERSANA Life SciencescoreChannel Partner/ Reseller/ DistributorEvoke has an agreement with EVERSANA for the complete commercialization of GIMOTI in the United States. Through this partnership, Evoke leverages EVERSANA's suite of capabilities and experts to implement their commercial strategy. The collaboration offers seamless integrated advantage across sales, marketing, access and reimbursement services, adherence, product distribution, and other services.

Scale indicators7 records

Recent moves8 records

Expansion highlights4 records

Evoke Pharma competitors and assessment

Company assessment

Broad incumbents

  • Salix Pharmaceuticals: Salix (now part of Bausch Health) is one of the largest US gastroenterology specialty pharmaceutical companies with a broad GI portfolio including treatments for IBS, bowel prep, and hepatic encephalopathy. Highly comparable business model of focused GI specialty drug commercialization, though at much larger scale than Evoke.

Direct peers

  • Ironwood Pharmaceuticals: Ironwood commercializes LINZESS (linaclotide) for IBS-C and CIC, making it a direct GI specialty pharma peer. Both companies operate single-asset or focused-portfolio commercial models targeting gastroenterologists and primary care, with similar reliance on prescriber adoption and payer access.
  • RedHill Biopharma: RedHill is a specialty pharma focused on gastrointestinal diseases, with commercial products for H. pylori, IBS, and gastroenteritis. Highly comparable as a small-cap GI specialty commercial-stage company, though RedHill operates across multiple assets rather than a single product.
  • Ardelyx: Ardelyx commercializes IBSRELA (tenapanor) and XPHOZAH for hyperphosphatemia, both targeting GI and renal specialists. Comparable as a small-cap GI-focused specialty commercial pharma with similar single-asset dynamics and prescriber-focused commercial model.
  • Phathom Pharmaceuticals: Phathom commercializes VOQUEZNA (vonoprazan) for H. pylori and erosive esophagitis. Directly comparable as a small-cap GI specialty commercial pharma with a novel mechanism product targeting gastroenterologists, with a similar prescriber-driven commercial model.
  • Sebela Pharmaceuticals: Sebela is a private specialty pharmaceutical company with multiple GI and women's health products, including treatments for bowel prep and IBS. Comparable as a privately held GI specialty pharma with similar commercial scale and prescriber-focused business model.
  • Aytu BioPharma: Aytu BioPharma is a small specialty pharmaceutical company commercializing products in pediatrics, respiratory, and GI. Relevant as a small-cap specialty pharma with GI exposure and similar commercial scale dynamics; Aytu's CCO Greg Pyszczymuka recently joined Evoke's board, signaling industry overlap.

Others

  • QOL Medical: QOL Medical is the parent company that acquired Evoke Pharma in December 2025. Relevant as the strategic acquirer and now owner of GIMOTI; QOL focuses on rare and specialty diseases and is itself a small specialty pharma.

Regional players

  • US WorldMeds: US WorldMeds is a privately held specialty pharma with a portfolio spanning gastroenterology, rare diseases, and neurology. Comparable as a privately held specialty commercial-stage pharma with GI exposure, though broader in scope.

Emerging players

  • Napo Pharmaceuticals: Napo (now Jaguar Health) commercializes Mytesi (crofelemer) for HIV-related diarrhea and is developing treatments for GI-related conditions. Comparable as a small specialty GI pharma with a single primary commercial asset and similar prescriber-focused commercialization dynamics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Evoke Pharma social profiles

Digital presence

Evoke Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evoke Pharma leadership team

Management profile

Number of profiles

Profiles11 records

Evoke Pharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evoke Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evoke Pharma

What does Evoke Pharma do?

Evoke Pharma develops and commercializes GIMOTI, a metoclopramide nasal spray that is the first and only FDA-approved non-oral treatment for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. The nasal route bypasses the gastrointestinal tract to provide more predictable drug absorption even during gastroparesis flares or vomiting, addressing a key gap left by oral metoclopramide approved since 1979. Evoke commercializes GIMOTI in the United States through a partnership with EVERSANA Life Sciences.

Is Evoke Pharma a public or private company?

Evoke Pharma is a public company. It is classified as corporate owned and is currently acquired.

When was Evoke Pharma founded?

Evoke Pharma was founded in 2007. It employs 11 to 50 people.

Where is Evoke Pharma based?

Evoke Pharma is headquartered in Solana Beach, United States, in the North America region.

How does Evoke Pharma make money?

One revenue line is on record: GIMOTI Product Sales.

Who are Evoke Pharma's main competitors?

Salix Pharmaceuticals is listed as a broad incumbent. Direct peers are Ironwood Pharmaceuticals, RedHill Biopharma, Ardelyx, Phathom Pharmaceuticals, Sebela Pharmaceuticals and Aytu BioPharma. QOL Medical is listed as an others. US WorldMeds is listed as a regional player. Napo Pharmaceuticals is listed as an emerging player.

Does Evoke Pharma have an API?

No public API is recorded for Evoke Pharma.

What industry is Evoke Pharma in?

Evoke Pharma's product category is Specialty Pharmaceuticals — Gastrointestinal Therapeutics. Its primary akta.pro industry code is HLAIACAE, Gastroenterology Specialty Pharmaceuticals, with a secondary code of HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireGIMOTI Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and JapanA new market report projects strong commercial growth for Evoke Pharma's GIMOTI nasal spray, with sales expected to reach USD 10.2 million in 2024 and Q2 2025 reaching USD 3.8 million, representing 47% year-over-year growth. The report covers seven major markets and highlights key growth drivers including a 46% increase in prescribers, a 72% rise in prescription fill rates, and real-world evidence showing over USD 15,000 in healthcare cost savings per patient within six months. A newly issued US patent extends GIMOTI's market exclusivity until November 2038, further solidifying its competitive positioning against oral metoclopramide therapies.openPR.comUnited States Diabetic Gastroparesis Treatment Market 2026 | Growth Drivers, Key Players & Investment OpportunitiesThe Global Diabetic Gastroparesis Treatment Market was valued at US$ 3.1 billion in 2022 and is projected to reach US$ 4.2 billion by 2030, growing at a CAGR of 3.8% during the forecast period 2023-2030. Key industry developments include Renexxion receiving U.S. FDA clearance in March 2024 for naronapride to enter clinical studies, Evoke Pharma strengthening commercialization of GIMOTI nasal spray in December 2025, and multiple companies advancing clinical programs for gastroparesis treatments in the United States and Japan.PR NewswireEvoke Pharma and QOL Medical Announce Expiration of Tender OfferQOL Medical, LLC completed its acquisition of Evoke Pharma, Inc. after a tender offer expired with approximately 67.63% of shares tendered at $11.00 per share. As a result of the merger, Evoke became a wholly owned subsidiary of QOL Medical and its shares were delisted from Nasdaq. This transaction marks the full integration of Evoke into QOL Medical's portfolio of specialty biopharmaceutical products.Investing.comEvoke Pharma acquired by QOL Medical, shares to be delisted from Nasdaq By Investing.comQOL Medical completed its acquisition of Evoke Pharma on December 17, 2025, by purchasing all outstanding shares for $11.00 in cash, resulting in Evoke Pharma becoming a wholly owned subsidiary. Consequently, Evoke Pharma's stock will be delisted from Nasdaq and it will terminate its SEC reporting obligations. The transaction, which closed after approximately 67.63% of shares were tendered, marks a strategic expansion for QOL Medical into the biopharmaceutical sector.Financial TimesEvoke Pharma and QOL Medical Announce Expiration of Tender Offer – Company AnnouncementEvoke Pharma and QOL Medical announced the expiration of QOL Medical's tender offer on December 15, 2025, with approximately 67.63% of Evoke shares (about 1,164,862 shares) validly tendered at $11.00 per share in cash. Following the offer's expiration, the merger was consummated and Evoke became a wholly owned subsidiary of QOL Medical, with all remaining shares converted to the right to receive the offer price. Evoke's common stock has ceased trading on Nasdaq as of December 17, 2025, and the company intends to promptly delist and deregister its shares.Financial TimesEvoke Pharma and QOL Medical Announce Expiration of Tender Offer – Company AnnouncementQOL Medical, through its wholly owned subsidiary Merger Sub, announced the expiration of its tender offer to acquire all outstanding shares of Evoke Pharma at $11.00 per share in cash, with the offer expiring on December 15, 2025 without extension. Approximately 1,164,862 shares were validly tendered, representing 67.63% of Evoke's total outstanding shares, and the merger was subsequently consummated, making Evoke a wholly owned subsidiary of QOL Medical. Evoke's common stock ceased trading on Nasdaq on December 17, 2025, and the company intends to delist and deregister its shares under the Securities Exchange Act.PR Newswire$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-COMP, HFWA, EVOK, and JTAIMonteverde & Associates PC, a New York-based securities class action law firm, announced legal inquiries into four separate merger transactions: Compass Inc.'s proposed merger with Anywhere Real Estate Inc., Heritage Financial Corporation's merger with Olympic Bancorp Inc., Evoke Pharma Inc.'s sale to QOL Medical LLC at $11.00 per share, and Jet.AI Inc.'s proposed merger with flyExclusive Inc. The firm is seeking shareholders of these companies to potentially join class action litigation, offering free consultations while advertising its track record of recovering millions for shareholders.GlobeNewswireEvoke Pharma Reports Third Quarter 2025 Financial Results and Provides Business UpdateEvoke Pharma, Inc. announced it has entered into a definitive merger agreement with QOL Medical, LLC, pursuant to which QOL Medical will acquire all outstanding shares of Evoke for $11.00 per share in cash, expected to close in Q4 2025 pending tender conditions. The specialty pharmaceutical company also reported Q3 2025 net product sales of $4.3 million, representing a 61% increase year-over-year, and received a new U.S. patent for GIMOTI extending exclusivity through November 2038.PR Newswire$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUEMonteverde & Associates PC is investigating several companies due to proposed mergers and sales, including Huntington Bancshares Incorporated, Avadel Pharmaceuticals, Evoke Pharma, and TrueCar. The investigations concern various merger terms and sale prices, with shareholders potentially entitled to recover damages.